Sildenafil dose in pphn in 1 day baby
Reading File
Checking Date & Time
Finding Sources
Searching PubMed
sildenafil PPHN neonate newborn dosing
Finding Sources
Searching PubMed
sildenafil "persistent pulmonary hypertension" newborn
Finding Sources
Reading Article
PMID: 39487423
Reading Article
PMID: 38363176
Finding Sources
Finding Sources
Reading File
I now have enough information to provide a comprehensive answer. Here is the summary:
Sildenafil in PPHN — Day 1 Neonate
Why Sildenafil?
Sildenafil is a PDE-5 inhibitor that prevents breakdown of cGMP, potentiating nitric oxide–mediated pulmonary vasodilation. It is used as adjuvant/alternative therapy when inhaled nitric oxide (iNO) is unavailable (the only FDA-approved agent for PPHN).
Dose (Oral/Enteral)
| Parameter | Recommendation |
|---|---|
| Route | Oral / nasogastric (IV formulation rarely used in neonates) |
| Dose | 0.5–1 mg/kg/dose (starting dose; some protocols use up to 2 mg/kg/dose) |
| Frequency | Every 6–8 hours (q6h–q8h) |
| Usual range | 1–3 mg/kg/dose q6–8h (as used in trials) |
In a 2024 network meta-analysis (Fei et al., Crit Care Med 2024, PMID 38363176, 23 RCTs, 902 neonates), the most effective PPHN treatment was iNO + oral sildenafil 1–3 mg/kg/dose q6–8h. When iNO is unavailable, sildenafil + milrinone was ranked second best.
A 2024 RCT (Kallimath et al., BMC Pediatrics, PMID 39487423) used oral sildenafil in term/late-preterm neonates with PPHN and showed significantly faster reduction in pulmonary artery systolic pressure vs. bosentan (median 36h vs. 96h).
Important Considerations in a 1-Day-Old
| Point | Detail |
|---|---|
| Age caution | Sildenafil is off-label in neonates. Use with careful monitoring. |
| FDA warning | The FDA issued a warning against sildenafil in pediatric PAH (children 1–17 years) at higher doses due to increased mortality — this is separate from neonatal PPHN and should not preclude short-term neonatal use. |
| Systemic hypotension | Major risk. Monitor BP closely. Start at the lower end (0.5–1 mg/kg/dose). |
| Hepatic metabolism | Immature CYP3A4 in neonates — half-life is prolonged; q8h dosing preferred on day 1. |
| Availability | Oral sildenafil can be compounded as a 1 mg/mL suspension for neonatal use. |
| Combination | Most effective when used alongside iNO; if no iNO, consider adding milrinone. |
Practical Approach for a 1-Day-Old with PPHN
- First-line: iNO at 20 ppm (if available) + optimize ventilation
- Add sildenafil: 0.5–1 mg/kg PO/NG q8h, increase to q6h if tolerated and response is partial
- Monitor: SpO2, pre/post-ductal saturations, echo (PASP), BP
- Escalate: If refractory → milrinone IV, ECMO
Sources: Barash's Clinical Anesthesia 9e; Fei et al., Crit Care Med 2024 [PMID 38363176]; Kallimath et al., BMC Pediatrics 2024 [PMID 39487423]
⚠️ Always verify doses against your institutional neonatal formulary (e.g., Neofax/Lexicomp) and consult a neonatologist before administration.
This is a shared conversation. Sign in to Orris to start your own chat.